ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学会発表・講演等
  2. 口頭発表

Fatty acid synthase is a key target to suppress tumor multiple functions: [1-11C]acetate PET as a predictor of the targeted therapy outcome

https://repo.qst.go.jp/records/64721
https://repo.qst.go.jp/records/64721
f82aaa3a-41b1-4a08-b7eb-fac831eb6800
Item type 会議発表用資料 / Presentation(1)
公開日 2012-09-12
タイトル
タイトル Fatty acid synthase is a key target to suppress tumor multiple functions: [1-11C]acetate PET as a predictor of the targeted therapy outcome
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_c94f
資源タイプ conference object
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 Yoshii, Yukie

× Yoshii, Yukie

WEKO 637721

Yoshii, Yukie

Search repository
Furukawa, Takako

× Furukawa, Takako

WEKO 637722

Furukawa, Takako

Search repository
Oyama, Nobuyuki

× Oyama, Nobuyuki

WEKO 637723

Oyama, Nobuyuki

Search repository
Kiyono, Yasushi

× Kiyono, Yasushi

WEKO 637724

Kiyono, Yasushi

Search repository
Nishii, Ryuichi

× Nishii, Ryuichi

WEKO 637725

Nishii, Ryuichi

Search repository
Tsuji, Atsushi

× Tsuji, Atsushi

WEKO 637726

Tsuji, Atsushi

Search repository
Sogawa, Chizuru

× Sogawa, Chizuru

WEKO 637727

Sogawa, Chizuru

Search repository
Wakizaka, Hidekatsu

× Wakizaka, Hidekatsu

WEKO 637728

Wakizaka, Hidekatsu

Search repository
Yoshii, Hiroshi

× Yoshii, Hiroshi

WEKO 637729

Yoshii, Hiroshi

Search repository
Fujibayashi, Yasuhisa

× Fujibayashi, Yasuhisa

WEKO 637730

Fujibayashi, Yasuhisa

Search repository
Saga, Tsuneo

× Saga, Tsuneo

WEKO 637731

Saga, Tsuneo

Search repository
et.al

× et.al

WEKO 637732

et.al

Search repository
吉井 幸恵

× 吉井 幸恵

WEKO 637733

en 吉井 幸恵

Search repository
古川 高子

× 古川 高子

WEKO 637734

en 古川 高子

Search repository
清野 泰

× 清野 泰

WEKO 637735

en 清野 泰

Search repository
西井 龍一

× 西井 龍一

WEKO 637736

en 西井 龍一

Search repository
辻 厚至

× 辻 厚至

WEKO 637737

en 辻 厚至

Search repository
曽川 千鶴

× 曽川 千鶴

WEKO 637738

en 曽川 千鶴

Search repository
脇坂 秀克

× 脇坂 秀克

WEKO 637739

en 脇坂 秀克

Search repository
吉井 裕

× 吉井 裕

WEKO 637740

en 吉井 裕

Search repository
藤林 康久

× 藤林 康久

WEKO 637741

en 藤林 康久

Search repository
佐賀 恒夫

× 佐賀 恒夫

WEKO 637742

en 佐賀 恒夫

Search repository
抄録
内容記述タイプ Abstract
内容記述 Objectives: Fatty acid synthase (FASN) is known to be over-expressed in several human cancers, e.g., prostate, breast, lung, and melanoma, and the over-expression is associated with poor prognosis (1). It is so far reported that orlistat, an inhibitor of FASN, shows antitumor effects (2). Hence, FASN is expected to be a promising therapeutic target for treatment of such cancers. However, large variations in FASN expression in individual tumors have been observed by pathological studies (3, 4), and therefore a method to predict therapeutic outcome of FASN-targeted therapy is needed to provide successful therapy for individual tumors. Also, how FASN inhibition affects tumor growth is still an open question. Here we examined whether [1-11C]acetate PET can evaluate FASN expression and predict outcome of FASN-targeted therapy, together with consequence of FASN inhibition in cancer therapy. Methods: Relationships between radiolabeled acetate uptake, FASN expression and therapeutic effect of orlistat were examined in vitro and in vivo with human prostate cancer cell lines including LNCaP, PC3, 22Rv1 and DU145. For in vitro studies, acetate uptake, FASN expression, and cell viability after orlistat treatment were determined. For in vivo studies, [1-11C]acetate PET, biodistribution study, and orlistat treatment (250 mg/kg/day for 2 weeks) were performed with tumor-bearing mice. To understand the mechanism how FASN inhibition affects tumor growth, FASN knockdown LNCaP cells were established by transduction of lentiviral particles carrying expression cassettes encoding single-hairpin RNA (shRNA) against FASN and the characteristics of the cells were examined in detail. Results: LNCaP cells, which express high levels of FASN, showed high acetate uptake, while PC3, 22Rv1 and DU145, which express low levels of FASN, showed relatively low acetate uptake. There was a significant positive correlation between acetate uptake and FASN expression. Percentage of cell viability after orlistat treatment showed significant negative correlations to acetate uptake and FASN expression, respectively. From in vivo studies, LNCaP tumors (high FASN) showed high acetate uptake and high sensitivity to orlistat treatment, while PC3 and DU145 tumors (low FASN) showed low acetate uptake and low sensitivity to orlistat treatment. Interestingly, we found that knockdown of FASN by shRNA suppressed cell proliferation, cell adhesion, migration and invasion with down-regulation of genes related to these functions. Conclusions: Our findings showed that FASN is a key target to suppress multiple steps related to tumor progression and [1-11C]acetate PET is a powerful tool to accomplish individualized FASN-targeted therapy by non-invasively predicting the therapeutic outcome.
会議概要(会議名, 開催地, 会期, 主催者等)
内容記述タイプ Other
内容記述 2012 World Molecular Imaging Congress
発表年月日
日付 2012-09-08
日付タイプ Issued
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 21:08:24.081964
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3